US 12,144,802 B2
Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
David W. Osborne, Fort Collins, CO (US); Babak N. Tofig, Westlake Village, CA (US); and Frank Watanabe, Westlake Village, CA (US)
Assigned to ARCUTIS BIOTHERAPEUTICS, INC., Westlake Village, CA (US)
Filed by ARCUTIS BIOTHERAPEUTICS, INC., Westlake Village, CA (US)
Filed on Jun. 30, 2023, as Appl. No. 18/217,287.
Claims priority of provisional application 63/406,921, filed on Sep. 15, 2022.
Prior Publication US 2024/0108609 A1, Apr. 4, 2024
Int. Cl. A61K 31/44 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/22 (2006.01)
CPC A61K 31/44 (2013.01) [A61K 9/0014 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/22 (2013.01)] 20 Claims
 
1. A topical pharmaceutical composition comprising a pharmaceutically effective amount of roflumilast, water, and a pharmaceutically acceptable solvent selected from the group consisting of 1,3-butylene glycol, 1,2-hexanediol, 1,3-propanediol, 1,2-pentanediol, dipropylene glycol, 2-(2-butoxy-ethoxy) ethanol, 1,6-hexanediol, propylene glycol methyl ethyl acetate, 5-methyloxolan-2-one, pantolactone, and combinations thereof.